Acne-Safe Formulation Principles: Non-Comedogenic Rating & Comedogenicity Testing

Overview #

Comedogenicity is one of those brief requirements that looks simple on paper and gets complicated fast. When a brand tells us “non-comedogenic, acne-safe,” we don’t just swap out a few oils and call it done. We’re making a series of interconnected formulation decisions — emulsifier selection, occlusion level, film-former choice, preservative system — that collectively determine whether a product clogs pores or doesn’t. And the rating systems most brands reference? They’re older than most of the actives we’re working with today. So before we talk about rabbit ear scores and INCI lists, let’s talk about what “acne-safe” actually means in a development brief, and what it costs to get there properly.

What “Non-Comedogenic” Actually Means in a Brief #

When a brand partner walks in with this requirement, the first question we ask is: are you targeting acne-prone skin as a primary claim, or is this a “won’t cause breakouts” reassurance for a general moisturizer? That distinction drives everything downstream.

The classic comedogenicity rating scale — 0 to 5, developed from rabbit ear assays in the 1970s and 1980s — is still widely cited in ingredient databases. A score of 0–1 is generally considered safe for acne-prone skin; 2 is borderline depending on concentration; 3 and above we avoid in leave-on products for this category. But here’s what that scale doesn’t tell you: it was developed on undiluted raw materials applied to rabbit ear follicular epithelium. In a finished formulation at 2–5% usage level, a “3-rated” ingredient may behave completely differently. We’ve run finished-product comedogenicity assessments on formulas containing borderline ingredients at low concentrations and seen clean results.

That said, we don’t use this as an excuse to sneak in problematic materials. Our internal rule is: if an ingredient scores 3 or above on the Kligman-Mills scale, it needs a strong functional justification and a finished-product test to back it up. No exceptions for leave-on face products.

The regulatory picture is worth understanding here. Neither the FDA Cosmetics Guidelines nor the EU Cosmetics Regulation 1223/2009 define “non-comedogenic” as a regulated claim. It’s a marketing term. Which means the burden of substantiation falls entirely on the brand — and by extension, on us as the formulating partner. We take that seriously because our clients’ claims are ultimately our formulation’s reputation.

For brands targeting the US market specifically, the FDA’s position is that comedogenicity testing methodology is not standardized. For EU-facing SKUs, the SCCS Scientific Opinion framework for ingredient safety assessment is the closest thing to a reference standard, though it doesn’t mandate specific comedogenicity protocols either. What this means practically: you need a defensible testing protocol, documented ingredient selection rationale, and ideally a human clinical study. We’ll come back to that.

Ingredient Architecture: Where the Real Decisions Happen #

This is usually where projects go sideways. Brands focus on the hero active — niacinamide, salicylic acid, azelaic acid — and underestimate how much the base formulation matters. We’ve seen a well-dosed 2% salicylic acid serum completely undermined by an emulsifier system that was borderline occlusive. The active was right. The base failed.

Our acne-safe formulation framework starts with four ingredient categories that require explicit sign-off before we proceed:

Emollients and oils. This is the highest-risk category. Isopropyl myristate (comedogenicity score: 5), isopropyl palmitate (score: 4), and coconut oil (score: 4) are the most common offenders we see in briefs from brands who’ve copied a competitor formula without understanding it. We default to squalane (score: 0–1), caprylic/capric triglyceride (score: 1), and hemp seed oil (score: 0) for acne-safe positioning. Jojoba oil sits at 2 — usable at concentrations below 3%, but we flag it.

Emulsifiers. PEG-based emulsifiers are a mixed picture. Some are fine; some aren’t. We’ve moved most of our acne-safe base formulas toward sucrose ester and polyglyceryl-based systems. They’re more expensive — roughly 15–25% higher raw material cost compared to conventional PEG emulsifiers — but the comedogenicity profile is cleaner and they test better in our internal assessments.

Film formers and polymers. This is an underappreciated risk area. Certain acrylate copolymers used for texture and skin feel can create an occlusive film that traps sebum. We’ve had one project — a hybrid SPF moisturizer for an acne-prone positioning — where the film former was creating a measurable increase in sebum accumulation under the film at 8 hours post-application. We caught it in consumer perception testing, not in the lab. That was a painful reformulation cycle.

Preservatives. For acne-prone skin, we generally avoid parabens not because of safety concerns — the SCCS Scientific Opinion data on methylparaben and ethylparaben is actually quite reassuring — but because the clean beauty positioning that typically accompanies acne-safe claims makes parabens commercially difficult. Our go-to system for this category is phenoxyethanol at 0.8–1.0% combined with ethylhexylglycerin at 0.3%. It’s effective, it’s clean-label friendly, and it passes our challenge testing at pH 5.0–6.0, which is where most of our acne-safe formulas sit.

For brands developing acne-adjacent products, our acne & blemish control formulation resources cover the active ingredient side in more depth. The base formulation decisions described here apply across that entire category.

The Testing Stack: What You Actually Need #

Here’s where we have an honest conversation with every brand partner. There are three levels of comedogenicity substantiation, and they’re not interchangeable.

Level 1: Ingredient-level screening. We cross-reference every INCI against the Kligman-Mills database and our internal expanded database, which includes more recent in vitro data. This takes 2–3 days and costs nothing extra — it’s part of our standard formulation process. It’s necessary but not sufficient for a non-comedogenic claim.

Level 2: In vitro follicular penetration or sebocyte assay. We work with two third-party labs that run these. Turnaround is typically 4–6 weeks, cost is approximately $1,500–$2,500 USD per formula. This gives you a defensible data point for the finished formulation, not just the ingredients. We recommend this as the minimum for any brand making an explicit non-comedogenic claim.

Level 3: Human clinical study. This is the gold standard. A properly designed comedogenicity study runs 8–12 weeks, requires a minimum of 30 subjects (we typically recommend n=40 for statistical robustness), and costs $8,000–$15,000 USD depending on the CRO and study design. For premium positioning or any brand planning to use “clinically tested non-comedogenic” in marketing copy, this is non-negotiable.

The clinical evidence for this approach is meaningful. One double-blind, randomized controlled study (n=44, 12 weeks) evaluating a niacinamide-based acne-safe moisturizer against an untreated control showed a 34% reduction in comedone count and a 28% reduction in inflammatory lesion count at week 12. What that study also showed — and what the abstract doesn’t emphasize — is that the vehicle formulation in the control arm was specifically designed to be comedogenically neutral. The active ingredient effect was real, but it was only visible because the base wasn’t confounding the results. That’s the point. A clean base isn’t just a safety requirement; it’s a study design requirement.

For brands also developing barrier-focused or sensitive skin variants alongside their acne line, our barrier repair and sensitive skin formulation notes are worth reviewing — the pH and emollient selection principles overlap significantly.

Development Tiers: Mass Market vs. Premium Acne-Safe #

We get briefs across the full spectrum. A mass-market acne moisturizer for a drugstore brand has completely different constraints than a premium acne-safe serum for a DTC brand charging $65 retail. The formulation principles are the same; the ingredient budget, testing investment, and packaging decisions are not.

A few things worth flagging on that table. The airless pump at premium tier adds $0.40–$0.80 per unit at MOQ 1,000. Most indie brands absorb this because the packaging story matters for their positioning. At mass market MOQ of 5,000 units, that same packaging decision adds $2,000–$4,000 to the total order cost — and suddenly the brand is asking whether a standard pump with a good formula is good enough. Usually it is.

The development timeline difference between tiers is real and mostly driven by testing, not formulation. We can develop a solid mass-market acne moisturizer formula in 6–8 weeks. The remaining time is stability testing, challenge testing, and — at premium tier — clinical study execution. Brands that come to us expecting a 10-week turnaround on a clinically substantiated premium product are going to be disappointed. We’d rather have that conversation at kickoff than at week 9.

Where Most Brands Get This Wrong #

Honestly, the most common mistake we see is treating “non-comedogenic” as an ingredient checklist rather than a systems question. A brand will send us a brief with a list of “approved” ingredients — all scoring 0–1 on the Kligman-Mills scale — and expect that a formula built from those ingredients is automatically non-comedogenic. It’s not that simple.

Concentration matters. Interaction effects matter. The ratio of occlusive to non-occlusive emollients matters. We’ve formulated products where every single ingredient was rated 0–1 and the finished product still showed borderline results in sebocyte assay because the total occlusion level was too high. The individual ingredients were fine. The combination wasn’t.

The other failure mode we see regularly: brands who want to add fragrance to an acne-safe product. We almost always push back on this brief. Not because fragrance is inherently comedogenic — most fragrance compounds score 0–1 — but because fragrance is the single biggest driver of contact sensitization in acne-prone skin, and sensitization triggers inflammation, and inflammation triggers breakouts. The mechanism is different from comedogenicity, but the outcome for the consumer is the same. We’ve stopped accepting fragrance in leave-on acne-safe formulas unless the brand has a very specific reason and accepts the risk in writing.

A lot of clean beauty brands also underestimate how fragile low-pH preservative systems become at production scale. At 500g lab scale, a phenoxyethanol system at pH 5.2 passes challenge testing cleanly. At 200kg production scale, we’ve seen gram-negative contamination appear at week 6 of post-challenge testing — not because the preservative was wrong, but because the mixing sequence and temperature profile at scale changed the effective pH by 0.3–0.4 units. That’s enough to push you out of the optimal efficacy window. We now require a pH verification step at three points during large-scale mixing, not just at the end.

Formulation Notes for Brand Partners #

What market? What are you expecting on-pack? Those are the first two questions we ask in every acne-safe brief. Because “non-comedogenic” means different things depending on whether you’re selling into the US, EU, or APAC markets — and the claim substantiation requirements follow from that.

If you’re a DTC brand targeting US acne-prone consumers and you want “clinically tested non-comedogenic” on pack, budget for a human study and a 20–24 week development timeline. If you’re launching a clean beauty line where “non-comedogenic” is a reassurance claim rather than a hero message, ingredient-level screening plus an in vitro assay is probably sufficient and gets you to market in 14–16 weeks.

Tell us your hero active upfront. Salicylic acid at 0.5–2.0% (OTC drug in the US, cosmetic in EU at ≤2%), niacinamide at 4–5%, azelaic acid at 10–20% — each of these drives different pH requirements, different emulsifier compatibility constraints, and different packaging decisions. The base formulation we build around a 1.5% salicylic acid serum at pH 3.5–4.0 looks nothing like the base we’d build around a 5% niacinamide moisturizer at pH 5.5–6.5.

Also tell us your texture expectation. Gel, lotion, cream, serum — these aren’t just aesthetic choices. They determine the emollient load, the film-former selection, and ultimately the occlusion level. A gel formula for acne-prone skin is inherently lower-risk from a comedogenicity standpoint than a cream. If your brand positioning requires a rich cream texture, we can get there, but it takes more careful ingredient selection and more testing investment to substantiate the claim.

We’re not going to tell you what you want to hear on timeline or cost. We’d rather give you an accurate picture at kickoff than a revised one at week 12.

Frequently Asked Questions #

Q: Can we just use an ingredient list from a competitor’s “non-comedogenic” product as our starting point?

We see this approach a lot, and it’s not a shortcut. Ingredient lists don’t tell you concentrations, mixing sequence, or pH — all of which affect comedogenicity outcomes. We’ll use it as a reference point, but we’re building from our own validated base formulas. Starting from a competitor INCI list typically adds 2–3 weeks of reverse-engineering work, not saves it.

Q: We want to claim “dermatologist-tested non-comedogenic” — what does that actually require?

At minimum, a finished-product human study with dermatologist oversight, minimum n=30 subjects, and a documented assessment protocol. We typically run these at n=40 over 8–12 weeks. The dermatologist involvement needs to be real — a sign-off on an ingredient list doesn’t qualify. Budget $8,000–$12,000 USD for a properly designed study.

Q: Is salicylic acid at 2% automatically safe for acne-prone skin, or does the base matter?

The base absolutely matters. Salicylic acid at 2% in a poorly designed base can still cause irritation-driven breakouts even if it’s technically clearing comedones. We formulate our salicylic acid systems at pH 3.5–4.0 for efficacy, with a carefully balanced emollient system to offset the drying effect. The active is only part of the story.

Q: We’re a clean beauty brand — can we get a non-comedogenic formula without any synthetic ingredients?

Mostly yes, but with trade-offs. Natural emollients like squalane (from sugarcane), hemp seed oil, and rosehip oil all score 0–1 on comedogenicity. The challenge is preservation — natural preservative systems are harder to validate at pH 5.0–6.0, and challenge test failure rates are higher in our experience. Expect a longer development cycle, roughly 4–6 additional weeks, and a higher formula cost, typically 20–35% above a comparable synthetic-inclusive formula.

Q: How long does stability testing take, and can we launch before it’s complete?

Our standard stability protocol runs 12 weeks at 40°C/75% RH per ICH Stability Guidelines, which is the accelerated equivalent of approximately 24 months real-time shelf life. We can provide a preliminary stability read at 4 weeks that covers the most critical failure modes. Some brands launch on the 4-week read with a commitment to pull product if the 12-week data shows issues. We support that approach but we document the risk clearly. We don’t recommend it for products with active ingredients at the edge of their stability window — salicylic acid and vitamin C formulas in particular.

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.